New research indicates that intact soluble urokinase plasminogen activator receptor (suPAR) does not induce albuminuria in mice. These data corroborate the most recent clinical findings, showing that intact suPAR is not the plasma permeability factor responsible for recurrence of focal segmental glomerulosclerosis after renal transplantation.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Serum C3 and Renal Outcome in Patients with Primary Focal Segmental Glomerulosclerosis
Scientific Reports Open Access 22 June 2017
-
The glomerular permeability factors in idiopathic nephrotic syndrome
Pediatric Nephrology Open Access 30 April 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Deegens, J. K. & Wetzels, J. F. Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial. Kidney Int. 80, 798–801 (2011).
Maas, R. J., Deegens, J. K. & Wetzels, J. F. Serum suPAR in patients with FSGS: trash or treasure? Paediatr. Nephrol. 28, 1041–1048 (2013).
Cathelin, D. et al. Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2013040425.
Rea, R., Smith, C., Sandhu, K., Kwan, J. & Tomson, C. Successful transplant of a kidney with focal segmental glomerulosclerosis. Nephrol. Dial. Transplant. 16, 416–417 (2001).
McCarthy, E. T., Sharma, M. & Savin, V. J. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 5, 2115–2121 (2010).
Wei, C. et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 17, 952–960 (2011).
Wei, C. et al. Modification of kidney barrier function by the urokinase receptor. Nat. Med. 14, 55–63 (2008).
Schlondorff, D. Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS? Kidney Int. 85, 499–501 (2014).
Meijers, B. et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int. 85, 636–640 (2014).
Bock, M. E., Price, H. E., Gallon, L. & Langman, C. B. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-centre report. Clin. J. Am.Soc. Nephrol. 8, 1304–1311 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Deegens, J., Wetzels, J. The search goes on: suPAR is not the elusive FSGS factor. Nat Rev Nephrol 10, 431–432 (2014). https://doi.org/10.1038/nrneph.2014.113
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2014.113
This article is cited by
-
Serum C3 and Renal Outcome in Patients with Primary Focal Segmental Glomerulosclerosis
Scientific Reports (2017)
-
The glomerular permeability factors in idiopathic nephrotic syndrome
Pediatric Nephrology (2016)
-
suPAR is the circulating factor in some but not all FSGS
Nature Reviews Nephrology (2014)
-
Measurement of serum suPAR is not ready for clinical use
Nature Reviews Nephrology (2014)